Opiant Pharmaceuticals (NASDAQ:OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.
Opiant Pharmaceuticals (NASDAQ:OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.